Last reviewed · How we verify
Autologous T-regulatory lymphocytes
At a glance
| Generic name | Autologous T-regulatory lymphocytes |
|---|---|
| Sponsor | Stanley H. Appel, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Controlling Hyperactive Immunity With Long-lived Lymphocytes (PHASE1, PHASE2)
- Safety and Efficacy of Treg Cell in the Treatment of GVHD (PHASE1, PHASE2)
- Treg Cell Therapy in Liver and Kidney Transplantation - Preclinical Validation of Batches of Treg Cells Amplified in Vitro (NA)
- Nivolumab With DC Vaccines for Recurrent Brain Tumors (PHASE1)
- Stem Cell Educator Therapy in Diabetes (PHASE2)
- T-Regulatory Cells in Amyotrophic Lateral Sclerosis (PHASE1)
- Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease (PHASE2)
- T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous T-regulatory lymphocytes CI brief — competitive landscape report
- Autologous T-regulatory lymphocytes updates RSS · CI watch RSS
- Stanley H. Appel, MD portfolio CI